Project Overview

P_ERP012611

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Visibility: Public
Publication: Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome Link
 Journal: Gut Microbes
Source: NA
Sample Number: 175

Samples in this project
  

SampleID Type Habitat Year Sequence type MNS1 MAS2
S_ERP012611.ERR1051173 Gut Feces 2012 16S - -
S_ERP012611.ERR1051174 Gut Feces 2012 16S - -
S_ERP012611.ERR1051175 Gut Feces 2012 16S - -
S_ERP012611.ERR1051176 Gut Feces 2012 16S - -
S_ERP012611.ERR1051177 Gut Feces 2012 16S - -
S_ERP012611.ERR1051178 Gut Feces 2012 16S - -
S_ERP012611.ERR1051179 Gut Feces 2012 16S - -
S_ERP012611.ERR1051180 Gut Feces 2012 16S - -
S_ERP012611.ERR1051181 Gut Feces 2012 16S - -
S_ERP012611.ERR1055226 Gut Feces 2012 16S - -
S_ERP012611.ERR1055227 Gut Feces 2012 16S - -
S_ERP012611.ERR1055228 Gut Feces 2012 16S - -
S_ERP012611.ERR1055229 Gut Feces 2012 16S - -
S_ERP012611.ERR1055230 Gut Feces 2012 16S - -
S_ERP012611.ERR1055231 Gut Feces 2012 16S - -

1MNS (Microbiome Novelty Score): < 0.12: Non-novel; 0.12-0.2: Novel; > 0.2: Very novel; -: NA for samples before 2010

2MAS (Microbiome Attention Score): < 10: Low-attention; ≥ 10: High-attention; -: NA for samples before 2010